Last updated: September 24, 2026
Dextromethorphan hydrobromide and promethazine hydrochloride is an established prescription oral cough-and-cold combination, generally marketed as an oral solution containing 15 mg dextromethorphan hydrobromide and 6.25 mg promethazine hydrochloride per 5 mL. The commercial opportunity is primarily in differentiated liquid formulations, dosing convenience, palatability, alcohol and sugar reduction, packaging, and supply reliability rather than new active-ingredient exclusivity.
The product has limited patent barriers because both active ingredients are old, small-molecule drugs. The principal development risks are formulation stability, preservative effectiveness, dose-measurement accuracy, pediatric safety, controlled-substance compliance for dextromethorphan, and FDA requirements for an abbreviated new drug application or other applicable pathway.
What is the approved formulation of dextromethorphan and promethazine?
The conventional product is an oral syrup or solution administered by mouth. A representative strength is:
| Component |
Amount per 5 mL |
| Dextromethorphan hydrobromide |
15 mg |
| Promethazine hydrochloride |
6.25 mg |
Dextromethorphan is an antitussive. Promethazine is a phenothiazine derivative with antihistamine and antiemetic activity. The combination is prescription-only in the United States and is not approved for children younger than two years because of the risk of fatal respiratory depression associated with promethazine-containing products. The FDA label also carries warnings involving sedation, respiratory depression, central nervous system depression, and interactions with monoamine oxidase inhibitors and other central nervous system depressants (FDA, 2023a; FDA, 2023b).
Commercial products commonly use a liquid vehicle containing some combination of sucrose, glycerin, purified water, alcohol, flavoring agents, acidulants, buffers, and preservatives. The exact inactive-ingredient profile varies by manufacturer and product code. A proposed generic formulation must be evaluated against the reference product for pharmaceutical equivalence, assay, impurities, stability, and bioequivalence where applicable.
Which excipients are most important for the formulation?
The highest-value excipient decisions involve solubility, taste, preservative performance, viscosity, and dose uniformity.
Solubilizers and co-solvents
Both active ingredients are water-soluble salts, allowing development of an aqueous oral solution. Alcohol, glycerin, propylene glycol, or combinations of these may be used to improve solubility, maintain clarity, control mouthfeel, and support flavor delivery.
An alcohol-containing formulation may simplify solubilization and preservation but creates commercial and regulatory disadvantages:
- Reduced acceptability for children and certain adult populations
- Religious, institutional, and abstinence-related concerns
- Potential labeling restrictions
- Greater scrutiny in products used for pediatric patients
- Lower suitability for hospitals, schools, and certain managed-care formularies
An alcohol-free product can create a meaningful point of differentiation if it maintains physical and chemical stability without excessive levels of propylene glycol or other co-solvents.
Sweeteners
Sucrose improves taste and viscosity but limits use by patients with diabetes, increases sugar exposure, and creates crystallization and microbial-control considerations. Sugar-free alternatives may use sorbitol, glycerin, sucralose, acesulfame potassium, or combinations of high-intensity sweeteners.
A sugar-free formulation has stronger commercial positioning for adult patients, institutional dispensing, and chronic metabolic-risk populations. The tradeoff is that polyols can cause gastrointestinal discomfort and may produce a less syrup-like mouthfeel. High-intensity sweeteners can leave bitterness or lingering aftertaste, which is especially relevant because both active ingredients can be difficult to mask.
Preservatives
Aqueous multi-dose products require a validated antimicrobial-preservation strategy unless the container and manufacturing system support another accepted control approach. Sodium benzoate and parabens are common options in oral liquids, although the selection must account for pH, preservative compatibility, taste, and regulatory expectations.
Preservative efficacy is affected by:
- Product pH
- Partitioning between aqueous and nonaqueous phases
- Container adsorption
- Microbial challenge profile
- Filling and closure conditions
- Use period after opening
The formulation should be evaluated under USP antimicrobial effectiveness testing and relevant stability protocols. Preservative selection can become a differentiator for clean-label positioning, but removing a preservative without a validated replacement increases microbiological risk.
Buffers and pH control
Citric acid, sodium citrate, phosphate systems, or other buffers may be used to maintain the target pH. pH affects active stability, preservative activity, flavor perception, color, and container compatibility.
The commercial objective is not simply to maximize chemical stability. A lower or higher pH can improve preservative performance while making the product more acidic, less palatable, or more irritating. The optimal pH should be selected through a formulation design space rather than by single-point screening.
Flavor systems
Taste masking is one of the main barriers to patient acceptance. Promethazine can contribute bitterness, while dextromethorphan has a strong medicinal taste. Citrus, berry, cherry, grape, vanilla, and mixed-fruit systems are plausible candidates, but flavor performance depends on sweetener, pH, viscosity, and preservative choice.
A two-stage flavor strategy is commercially useful:
- Screen broad flavor families in simple aqueous vehicles.
- Optimize the selected flavor in the final preservative, sweetener, buffer, and viscosity system.
Taste evaluation should include adult and pediatric proxy panels where permitted. The product must not be positioned for children younger than two years, regardless of flavor profile.
What formulations are protected by commercial opportunity rather than patents?
The strongest formulation opportunities are likely to come from product attributes that can be commercialized without relying on broad composition patents.
| Formulation concept |
Commercial value |
Main technical risk |
| Sugar-free oral solution |
Expands use among diabetic and calorie-conscious patients |
Bitter aftertaste, laxation from polyols |
| Alcohol-free solution |
Improves pediatric and institutional acceptability |
Solubility, preservation, microbial control |
| Unit-dose cups or sachets |
Reduces dosing errors and contamination |
Packaging cost and fill-volume accuracy |
| Child-resistant multidose bottle |
Supports pharmacy and home use |
Dose-measurement variability |
| Ready-to-use oral solution |
Simplifies administration |
Shelf-life and shipping stability |
| Higher-viscosity solution |
Improves mouthfeel and dose retention |
Pourability and content uniformity |
| Natural-flavor or low-dye product |
Supports retail differentiation |
Taste masking and color stability |
| Tamper-evident packaging |
Addresses diversion and product integrity |
Cost and packaging qualification |
The most defensible product differentiation would combine several attributes, such as alcohol-free, sugar-free, dye-free, child-resistant, and supplied with an oral dosing syringe. A single excipient substitution is less likely to produce durable commercial protection unless it creates a material improvement in stability, tolerability, or manufacturing efficiency.
How does the product compare with competing cough-and-cold formulations?
The combination competes with single-ingredient dextromethorphan products, promethazine-containing products, antihistamine-antitussive combinations, and nonprescription cough syrups.
| Product category |
Typical positioning |
Competitive advantage |
| Dextromethorphan-only syrup |
Cough suppression |
Lower sedative burden and broader OTC familiarity |
| Promethazine-only solution |
Allergy, nausea, sedation |
Established clinical familiarity |
| Dextromethorphan-promethazine solution |
Prescription cough relief with sedating antihistamine activity |
Combination dosing and physician familiarity |
| Dextromethorphan-guaifenesin product |
Cough suppression and expectoration |
Broad OTC availability |
| Nonprescription multi-symptom syrup |
Cough, cold, and flu symptoms |
Convenience and retail visibility |
The combination is less attractive for self-care because it is prescription-only and has meaningful sedation and respiratory-depression warnings. Its commercial value depends on prescriber recognition, pharmacy availability, and differentiated formulation attributes rather than broad consumer advertising.
What is the FDA regulatory status and development pathway?
A generic version normally would proceed through an ANDA if the reference product, dosage form, strength, route, and active ingredients satisfy the applicable requirements. The applicant must demonstrate pharmaceutical equivalence and bioequivalence and address inactive-ingredient differences under FDA requirements.
Key regulatory issues include:
- Correct strength and dosage form
- Equivalent route of administration
- Assay and degradation-product specifications
- Oral-solution uniformity
- Preservative content and effectiveness
- Container-closure integrity
- Extractables and leachables
- Stability through the proposed shelf life
- Accurate dosing-device performance
- Labeling consistent with the reference product
- Pediatric safety warnings
Because this is an oral solution rather than a tablet or capsule, the development program may focus heavily on comparative formulation data and product quality. A manufacturer cannot assume that a cosmetically different liquid has low regulatory risk. Differences in excipients can affect bioequivalence, tolerability, microbial quality, or labeling.
When does dextromethorphan-promethazine lose exclusivity?
The active ingredients have no meaningful new-molecule exclusivity remaining. The commercial protection of a current product depends on the status of the specific reference product, any listed patents, regulatory exclusivity, trademarks, and manufacturing know-how.
For this established combination, generic-entry risk is generally higher than for a newly approved branded drug. The relevant barriers are usually:
- ANDA approval timing
- Reference-product designation
- Patent certifications
- Manufacturing scale
- Product quality
- Pharmacy contracting
- Wholesale availability
The Orange Book should be reviewed for the specific reference product and NDA before filing or launch decisions. Patent status can differ by product, strength, dosage form, and sponsor. A formulation or method-of-use patent is not automatically enforceable against every generic product, and the absence of a broad composition patent does not eliminate litigation risk.
Which companies are challenging the product, and what is the Paragraph IV risk?
The product category is exposed to generic competition from manufacturers capable of producing prescription oral liquids. Paragraph IV risk depends on whether an applicant certifies that a listed patent is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger litigation and, in some cases, a 30-month stay under the Hatch-Waxman framework.
No biosimilar pathway applies because the product contains small-molecule active ingredients rather than a biologic. The principal competitive threat is therefore ANDA-based generic entry.
The most likely launch scenarios are:
| Scenario |
Commercial effect |
| One approved generic |
Moderate price pressure; limited supply disruption |
| Multiple liquid generics |
Rapid erosion in average selling price |
| Authorized generic plus ANDA entrants |
Earlier and deeper price compression |
| Shortage or manufacturing failure |
Temporary supply premiums for reliable suppliers |
| Differentiated alcohol-free or sugar-free product |
Partial insulation from commodity pricing |
Litigation risk is likely to concentrate on any later-added formulation or delivery patent rather than on the old active ingredients themselves.
How strong is the patent estate?
The active-ingredient patent estate is weak from a lifecycle-management perspective because dextromethorphan hydrobromide and promethazine hydrochloride are long-established compounds. New patent value would need to come from a specific formulation, manufacturing process, packaging system, dosing device, or clinically meaningful method of use.
Potentially patentable subject matter includes:
- A narrowly defined excipient ratio that improves stability or taste
- A low-alcohol or alcohol-free solvent system
- A preservative-free multidose container
- A controlled-viscosity oral solution
- A unit-dose package that limits dosing error
- A manufacturing process that reduces impurities
- A new flavor-masking system with measured sensory improvement
Patent strength would depend on unexpected results, narrow claim construction, freedom to operate, and whether competitors can design around the claimed excipient ranges. Broad claims covering an ordinary syrup containing standard sweeteners, buffers, and preservatives would face substantial validity and obviousness pressure.
What manufacturing and intellectual-property barriers matter most?
Manufacturing barriers are more significant than active-ingredient IP barriers. Oral liquids require reliable control of microbial quality, fill volume, active uniformity, viscosity, and container compatibility.
The highest operational risks are:
- Supplier concentration for pharmaceutical-grade flavors and preservatives
- Variation in raw-material particle size or assay
- Inadequate mixing of low-dose promethazine
- Preservative loss during storage
- Bottle or closure interactions
- Shipping excursions
- Oral-syringe compatibility
- Scale-up changes affecting taste and viscosity
A dual-source strategy for active ingredients, sweeteners, preservatives, and packaging components can protect continuity. The formulation should be designed for robust manufacturing rather than maximum excipient complexity.
What licensing and commercial opportunities exist?
Licensing opportunities are more likely to involve formulation platforms, contract manufacturing, or branded-generic distribution than exclusive rights to the active ingredients.
Attractive transaction structures include:
- In-licensing an alcohol-free or sugar-free formulation
- Contract development and manufacturing for regional generic suppliers
- Private-label supply for pharmacy and telehealth channels
- Co-development of unit-dose packaging
- Regional commercialization rights
- Supply agreements with hospital and institutional purchasers
- Authorized-generic arrangements with the reference-product holder
A formulation owner with validated stability, sensory data, and commercial-scale manufacturing can create value even without a broad composition patent. The strongest package would include regulatory-ready development data, a reliable contract manufacturer, a differentiated label claim, and evidence of pharmacy or institutional demand.
What revenue exposure and launch economics should investors assess?
Revenue exposure depends on whether the product is sold as a commodity generic or as a differentiated prescription liquid. Commodity products are vulnerable to rapid price decline when multiple suppliers enter. Differentiated products can preserve margin if the attributes solve a real procurement or patient-adherence problem.
Key commercial metrics include:
- Annual prescription volume
- Average net price per bottle
- Bottle size and refill frequency
- Pharmacy substitution rate
- Gross-to-net deductions
- Manufacturing cost per 5 mL dose
- Packaging cost per unit
- Stability-related inventory loss
- Shortage frequency among competitors
- Formulary and wholesaler access
A 4-ounce multidose bottle with a dosing device is likely to have different economics from a unit-dose cup or sachet. Packaging innovation can improve adherence and reduce dosing error but may erase margin if the product remains therapeutically substitutable with a low-cost syrup.
Key Takeaways
- The main opportunity is differentiated oral-liquid formulation, not new active-ingredient exclusivity.
- Alcohol-free and sugar-free products have the clearest commercial rationale.
- Taste masking, preservative performance, and dose-device accuracy are central development issues.
- The FDA pathway is generally an ANDA-based generic strategy for qualifying products.
- Biosimilar risk does not apply.
- Patent protection is likely to be narrow and formulation-specific.
- Generic price erosion is the principal commercial risk.
- Manufacturing reliability and pharmacy availability may create more value than broad patent coverage.
- Unit-dose packaging, child-resistant closures, and validated oral syringes can support premium positioning.
- Licensing opportunities are strongest in formulation platforms, contract manufacturing, private label, and regional commercialization.
FAQs
Is dextromethorphan-promethazine syrup an OTC product?
No. The combination is generally marketed as a prescription oral solution in the United States. Dextromethorphan alone is widely available in OTC products, but adding promethazine changes the regulatory and safety profile.
Can an alcohol-free formulation be commercially differentiated?
Yes. An alcohol-free product can address pediatric, institutional, religious, and patient-preference requirements. It must maintain solubility, chemical stability, preservative effectiveness, palatability, and shelf life without relying on ethanol.
Is a sugar-free formulation suitable for children?
A sugar-free formulation may improve suitability for some patients, but it does not remove the promethazine-related contraindication for children younger than two years. Pediatric labeling and safety restrictions remain controlling.
Can a new flavor be patented?
A flavor alone may provide limited patent value. A flavor system combined with a defined excipient composition and unexpected taste-masking or stability results may support stronger formulation claims.
What is the biggest barrier to launching a generic oral solution?
The largest barriers are usually regulatory product-quality requirements, manufacturing consistency, microbiological control, packaging qualification, and commercial access. The old active ingredients generally present less difficulty than the liquid formulation and supply chain.
References
-
U.S. Food and Drug Administration. (2023a). Promethazine hydrochloride and dextromethorphan hydrobromide oral solution: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2023b). Promethazine hydrochloride: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024b). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that reference listed drugs of rDNA origin. https://www.fda.gov/
-
United States Pharmacopeia. (2024). General chapter <51>: Antimicrobial effectiveness testing. United States Pharmacopeial Convention.
